Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Ophthalmol ; 22(1): 130, 2022 Mar 22.
Article in English | MEDLINE | ID: mdl-35317777

ABSTRACT

BACKGROUND: We aimed to analyze the clinical characteristics of secondary glaucoma related to cytomegalovirus (CMV)- and varicella zoster virus (VZV)-positive uveitis. METHODS: In this retrospective study, we enrolled patients with anterior uveitic secondary glaucoma. All the patients underwent aqueous and serum analyses for viral antibody through enzyme-linked immunosorbent assay. Among the 60 included patients, 22 had CMV-negative Posner-Schlossman syndrome (CMV-negative PSS), 25 had CMV-positive PSS, and 13 had VZV-positive anterior uveitis secondary glaucoma (VZV-AUSG). We evaluated the following main indicators: age, disease duration, intraocular pressure (IOP), cup-to-disc ratio, best corrected visual acuity (BCVA), corneal endothelial cell (CEC) count, ocular morphological changes, and medical treatments. RESULTS: We found that 53.2% (25/47) patients with PSS were CMV-positive. Patients with CMV-positive PSS had a larger cup-to-disc ratio (p = .043), lower CEC density (p = .017), more severe CEC loss (p < .001), and more iris depigmentation (p = .006) than CMV-negative PSS patients. Compared with patients with CMV-positive PSS, those with VZV-AUSG were older (p = .003), presented a higher IOP (p = .015), and had poorer BCVA (p < .001). Patients with CMV-positive PSS and VZV-AUSG all accepted ganciclovir treatment, and those with CMV-positive PSS used fewer antiglaucoma agents simultaneously compared with CMV-negative PSS (p = .005) and VZV-AUSG (p < .001). All three groups had a comparable proportion of patients requiring antiglaucoma surgery. CONCLUSIONS: We observed some distinctive clinical features in CMV-positive PSS compared with CMV-negative PSS. Further, we found that patients with VZV-AUSG presented with a higher IOP and worse visual acuity, and required more antiglaucoma medication than those with CMV-positive PSS.


Subject(s)
Cytomegalovirus Infections , Eye Infections, Viral , Glaucoma , Aqueous Humor , Cytomegalovirus/genetics , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/drug therapy , DNA, Viral/analysis , Eye Infections, Viral/complications , Eye Infections, Viral/diagnosis , Eye Infections, Viral/drug therapy , Glaucoma/etiology , Herpesvirus 3, Human , Humans , Retrospective Studies
2.
Biochem Biophys Res Commun ; 531(4): 452-458, 2020 10 22.
Article in English | MEDLINE | ID: mdl-32800548

ABSTRACT

Diabetic retinopathy (DR), a major cause of blindness in working-age people, is attributed to the inflammatory response of retinal Müller cells (RMCs). The heparanase inhibitor PG545 plays proautophagic and anti-inflammatory roles. Intraperitoneal injection of PG545 at a dose of 20 mg/kg/d clearly reduced diabetes-induced body weight changes and fasting blood glucose levels in mice. PG545 also mitigated the reduction in retinal thickness and the formation of microaneurysms by promoting autophagy to inhibit the inflammatory response. In vitro, PG545 stimulated autophagy to downregulate the inflammatory response in high glucose-induced primary adult mouse RMCs. These data suggest that PG545 mitigates DR by promoting RMC autophagy to inhibit the inflammatory response.


Subject(s)
Diabetic Retinopathy/drug therapy , Ependymoglial Cells/drug effects , Retinitis/drug therapy , Saponins/pharmacology , Animals , Autophagy/drug effects , Autophagy-Related Protein 7/genetics , Blood Glucose/metabolism , Body Weight , Cells, Cultured , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Diabetic Retinopathy/pathology , Ependymoglial Cells/pathology , Glucose/pharmacology , Male , Mice, Inbred C57BL , Mice, Mutant Strains , Retinitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...